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Abstract
Background: Invasive lobular carcinomas (ILCs) account for 10–15% of all breast cancers. They are characterized by
an elevated endocrine responsiveness and by a long lasting risk of relapse over time. Here we report for the first
time an analysis of clinical and pathological features associated with the risk of late distant recurrence in ILCs.
Patients and methods: We retrospectively analyzed all consecutive patients with hormone receptor–positive ILC
operated at the European Institute of Oncology (EIO) between June 1994 and December 2010 and scheduled to
receive at least 5 years of endocrine treatment.
The aim was to identify clinical and pathological variables that provide prognostic information in the period beginning
5 years after definitive surgery. The cumulative incidence of distant metastases (CI-DM) from 5 years after surgery was
the prospectively defined primary endpoint.
Results: One thousand eight hundred seventy-two patients fulfilled the inclusion criteria. The median follow-up was
8.7 years.
Increased tumor size and positive nodal status were significantly associated with higher risk of late distant recurrence,
but nodal status had a significant lower prognostic value in late follow-up period (DM-HR, 3.21; 95% CI, 2.06–5.01) as
compared with the first 5 years of follow-up (DM-HR, 9.55; 95% CI, 5.64–16.2; heterogeneity p value 0.002).
Elevated Ki-67 labeling index (LI) retained a significant and independent prognostic value even after the first 5 years
from surgery (DM-HR, 1.81; 95% CI 1.19–2.75), and it also stratified the prognosis of ILC patients subgrouped according
to lymph node status.
A combined score, obtained integrating the previously validated Clinical Treatment Score post 5 years (CTS5) and Ki-67
LI, had a strong association with the risk of late distant recurrence of ILCs.
Conclusion: We identified factors associated with the risk of late distant recurrence in ER-positive ILCs and developed
a simple prognostic score, based on data that are readily available, which warrants further validation.
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Introduction
Invasive lobular carcinoma (ILC) is the second most
common histologic subtype of breast cancer (BC) and
accounts for approximately 10–15% of all BCs. Com-
pared with invasive carcinoma nonspecial type (NST;
previously: invasive ductal carcinomas, IDC), it has dif-
ferent biology and natural history [1, 2].
Classic ILCs are typically of low or intermediate histo-
logic grade and low to intermediate mitotic index. More
than 90% of cases express estrogen (ER) and/or proges-
terone receptors (PgR) and rarely show HER2 protein
overexpression or gene amplification [3].
In gene expression profiling studies, more than 80% of
ILCs are classified as luminal A, with very few cases classi-
fied as HER2-enriched or basal-like molecular subtypes [2].
From a clinical perspective, these biological features
translate in an elevated endocrine responsiveness and
also in a peculiar pattern of risk of relapse, characterized
by a very long lasting risk over time [3, 4].
In a large stage-matched analysis with long follow-up, it
has been reported that ILC and IDC disease-free survival
(DFS) and overall survival (OS) curves crossed over time,
with an initial favorable prognosis for ILCs becoming un-
favorable with longer follow-up in this subgroup [4].
Results of studies exploring the efficacy of extended
endocrine therapy beyond 5 years showed that the risk
of late recurrence could be reduced [5–10].
Recognition of the magnitude of the residual recur-
rence risk of ER-positive BC patients after 5 years of
endocrine therapy is therefore useful, since it can help to
decide whether to extend therapy [ 5–10].
Several retrospective studies assessed the correlation
between the clinical and pathological features of ER-
positive BCs and the risk of distant recurrence after the
first 5 years of endocrine therapy [11–13].
Consistent results showed that the tumor size and
number of positive nodes were the strongest factors sig-
nificantly and independently associated with risk of late
distant recurrence [11–13].
For both factors, the strength of association with the
risk of distant recurrence was similar during both the
early and late periods of follow-up [11–13].
In contrast, other factors that were of some additional
prognostic relevance during the first 5 years were of less,
or no, additional relevance thereafter.
Tumor grade and Ki-67 labeling index (LI) were signifi-
cant independent prognostic factors during the first 5
years, but were of only small relevance thereafter [11–13].
PgR and HER2 status were independently associated with
the clinical outcome only during years 0 to 5 [11–13].
None of these studies took into account the histo-
logical subtype of BC analyzed.
Since the vast majority of ER+ BC are IDCs (currently,
invasive breast carcinoma NST), results obtained were
dominated by this tumor subtype. Uncertainty remains
on their validity for other BC subtypes, especially ILCs,
whose pattern of risk of relapse over time significantly
differs from that of IDCs [4].
Here we report for the first time an evaluation of the
influence of clinical and pathological characteristics on
late recurrence risk of women with ER-positive, early-
stage ILCs, who were scheduled to receive adjuvant
endocrine therapy for at least 5 years.
Methods
We extracted information from our prospectively col-
lected institutional database on all consecutive ILC pa-
tients operated at the European Institute of Oncology
(EIO) between June 1994 and December 2010.
We included in our analysis only hormone receptor–
positive ILCs (steroid hormone receptor status was clas-
sified as positive for ≥ 1% immunoreactive tumor cells).
Patients with a previous primary tumor, with a mixed
lobular/ductal histotype, or with missing information on
lymph nodes status, primary tumor size, ER and PgR sta-
tus, and Ki-67 LI were excluded.
Histological types were classified according to the
World Health Organization criteria and the Armed
Forces Institute of Pathology criteria [14, 15]. Tumor
grade, peritumoral vascular invasion (PVI), ER and PgR
status, Ki-67 LI, and HER2 overexpression and/or ampli-
fication were evaluated as previously reported [16–21].
The original pathology reports were used.
We also extracted a sub-cohort from the hormone re-
ceptor–positive IDCs treated at EIO in the same time
period. Patients in the sub-cohort were 1:1 matched to
patients in the ILC cohort according to patients’ age
group (< 50, 50–59, and ≥ 60 years old), nodal status, T
stage, year of surgery (before 2003, 2003–2006, 2007–
2010), and tumor subtype classification (luminal A-like
and luminal B-like according to St. Gallen 2013 classifi-
cation) [16–21].
Statistical analysis
The primary objective of this study was to determine
whether the clinical pathological features of ILCs pro-
vide prognostic information in the period beginning 5
years after definitive surgery.
The cumulative incidence of distant metastases (CI-
DM) from 5 years after surgery was the prospectively de-
fined primary endpoint.
The other endpoints evaluated were disease-free sur-
vival (DFS; measured both from the date of surgery and
from 5 years after surgery), overall survival (OS; mea-
sured from the date of surgery), and CI-DM measured
from the date of surgery.
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Active follow-up was conducted to determine patient
status as of July 2018. Surviving patients were censored
at the date of the last follow-up.
Patients were followed up with physical examination
every 6 months, annual mammography and breast ultra-
sound, blood tests every 6–12months, and further evalu-
ations only in case of symptoms.
When possible, the status of women not presenting at
the institute for scheduled follow-up visits for more than
1 year was obtained by telephone contact.
Events considered in the DFS computations were re-
lapse (categorized as loco-regional events, including ipsi-
lateral breast recurrence, and distant metastases),
appearance of a second primary cancer (including contra-
lateral breast cancer), or death, whichever occurred first.
OS was defined as the time from surgery until the date
of death (from any cause).
The DFS and OS functions were estimated using the
Kaplan–Meier method. The log-rank test was used to as-
sess differences between groups.
The CI-DM curve function was estimated according to
methods described by Kalbfleisch and Prentice, taking
into account the competing causes of recurrence. Gray’s
test was used to assess cumulative incidence differences
between groups [22, 23].
Univariable and multivariable Cox proportional hazard
regression models and Fine and Gray’s proportional sub-
distribution hazard models were used to assess the asso-
ciation of clinical and histopathologic characteristics of
the tumor on DFS and CI-DM, respectively. Factors in-
cluded in multivariable regression analyses were histo-
logical grade (G1/G2, G3), T stage (pT1/2, pT3/4), nodal
status (pN0, pN1/2/3), PgR (< 20% and ≥ 20%), Ki-67 (di-
vided using institutional median value as < 20%, ≥ 20%),
and HER2 overexpression (negative, positive) [17].
The heterogeneity of grade, tumor stage, nodal status,
PgR, Ki-67 LI, and HER2 effects on the risk of DM
within each considered time period (≤ 5 years versus > 5
years) was assessed by including interaction terms be-
tween the factor of interest and time period in the re-
gression models.
We also assessed the association between the Clinical
Treatment Score post 5 years (CTS5) and CI-DM after
the first 5 years of follow-up.
CTS5 is a prognostic tool to estimate risk of late dis-
tant recurrence that was developed and validated on the
TransATAC and BIG1-98 data set [24, 25].
The CTS5 model includes information on age (con-
tinuous, in years), tumor size (continuous, in cm),
quadratic tumor size, nodal status (five groups: 0,
negative; 1, one positive; 2, two to three positive; 3,
four to nine positive; and 4, nine positive), and grade
(three groups: 1, low; 2, intermediate; and 3, high)
and is given by:
CTS5 = 0.438 × nodes + 0.988 × (0.093 × tumor size −
0.001 × (tumor size)2 + 0.375 × grade + 0.017 × age) [24, 25].
The added prognostic values, beyond that obtained
from CTS5, of other factors such as the HER2 status,
the expression of ER, PgR, or Ki-67, was evaluated using
likelihood ratio test (LRT), comparing a regression
model with only CTS5 as covariate with a model includ-
ing CTS5 and the factor of interest [24, 25].
All analyses were performed with SAS software v. 9.4
(SAS Institute, Cary, NC). All tests were two-sided, and
p values < 0.05 were considered statistically significant.
Treatment received
All patients received breast conserving surgery or total
mastectomy, plus axillary sentinel lymph node biopsy or
complete axillary dissection [20].
Systemic adjuvant therapy was recommended accord-
ing to the contemporary St. Gallen treatment guidelines
[17, 20, 26–28].
We included patients that were scheduled to receive
endocrine therapy for at least 5 years, regardless of ac-
tual adherence.
Adjuvant endocrine therapy in pre-menopausal patients
included tamoxifen alone for 5 years or the combination
of tamoxifen for 5 years plus a luteinizing hormone releas-
ing hormone analog for a minimum of 2 years [20, 26]. In
post-menopausal patients, an aromatase inhibitor com-
monly formed part of endocrine therapy either as only
endocrine therapy for 5 years or after 2–3 years of tamoxi-
fen [17, 20, 26]. Post-menopausal patients at low risk or
with comorbidities received tamoxifen alone.
Details on adjuvant endocrine therapies are reported in
Table 1.
After 2005, patients with node-positive or node-negative
tumors with worse prognostic features may have been
treated with extended endocrine therapy for further 5 years
of treatment with tamoxifen if they were pre-menopausal pa-
tients or AI if they were post-menopausal [29].
In patients at higher risk and/or with features of un-
certain endocrine responsiveness, chemotherapy was
added [17, 20, 26]. Anthracycline-containing chemother-
apy [i.e., doxorubicin and cyclophoshamide (AC), for
four courses] was considered as the first option in pa-
tients with higher risk disease; in case of comorbidities
or patients’ preferences, classical CMF (oral cyclophos-
phamide, methotrexate, and fluorouracil) for three to six
courses was considered [30, 31].
Results
Clinical and pathological characteristics associated with
higher risk of late recurrence in ILCs
Between June 1994 and December 2010, 1872 patients
with hormone receptor–positive ILC operated at the
EIO fulfilled the inclusion criteria for the analysis.
Conforti et al. Breast Cancer Research          (2019) 21:153 Page 3 of 11
The baseline characteristics of patients are shown in
Table 1. The median follow-up time (FUP) was 8.7 years,
for a total of 13,883 person-years (PY).
We observed 520 DFS events of which 205 were dis-
tant metastases. Of these, 279 DFS events, including 116
distant metastases, occurred within the first 5 years and
241 DFS events, including 89 distant metastases, oc-
curred beyond 5 years after surgery (Additional file 1:
Table S1).
In the first 5 years of follow-up, the DFS and DM
yearly rates were 3.4% (95% CI, 3.0–3.8) and 1.4% (95%
CI, 1.2–1.7), respectively.
In the period beyond the first 5 years after surgery, the
DFS and DM yearly rates were 4.3% (95% CI, 3.8–4.9)
and 1.6% (95% CI, 1.3–1.9), respectively.
We first assessed the prognostic value of clinical and
pathological tumor features in predicting CI-DM and
DFS, separately in the first 5 years after surgery and be-
yond the first 5 years of FUP.
Univariable analyses showed that in the first 5 years of
follow-up, all variables analyzed had significant prognos-
tic value for DM (Table 2).
In the period beyond the first 5 years, factors signifi-
cantly associated with the risk of DM were positive
nodal status (HR, 3.21; 95% CI, 2.06–5.01), T3/4 stage
(HR, 3.31; 95% CI, 2.05–5.33), and high Ki-67 LI (HR,
1.81; 95% CI, 1.19–2.75; Table 2).
The strength of association with the risk of DM was
not significantly different in the first 5 years and in the
subsequent period of follow-up for Ki-67 LI and T stage
(Table 2).
Positive nodal status had a significant lower prognostic
value in the late follow-up period (HR, 3.21; 95% CI,
2.06–5.01) as compared with the first 5 years of FUP
Table 1 Distribution of patient baseline characteristics
Number Percentage
Age group
< 40 75 4.0
40–49 570 30.4
50–59 540 28.8
60+ 687 36.7
Median age (IQR) 54 (47–64)
Menopausal status
Pre-menopausal 788 42.1
Post-menopausal 1084 57.9
pN
pN0 1103 58.9
pN1 449 24.0
pN2 131 7.0
pN3 189 10.1
pT
pT1 1060 56.6
pT2 612 32.7
pT3/4 200 10.7
Tumor grade
G1 279 14.9
G2 1232 65.8
G3 209 11.2
Unknown 152 8.1
Vessel invasion
No 1797 96.0
Yes 75 4.0
Local treatment
Mastectomy w/o RT 355 19.0
Mastectomy w RT 245 13.1
Quadrantectomy w/o RT 36 1.9
Quadrantectomy w RT 1236 66.0
Adjuvant treatment
ET 1481 79.1
CT+ET 391 20.9
Hormonal therapy
Pre-menopausal
TAM 107 13.6
TAM+LHRH 556 70.5
AI+LHRH 58 7.4
Other 67 8.5
Post-menopausal
TAM 483 44.6
AI 463 42.7
Other 138 12.7
Table 1 Distribution of patient baseline characteristics
(Continued)
Number Percentage
Receptor status
Incompletely expressed (ER < 50 or PgR < 50) 841 44.9
Highly expressed (ER≥ 50 and PgR≥ 50) 1031 55.1
Ki-67
< 20% 1375 73.5
≥ 20% 497 26.5
HER2
Not expressed 1727 92.3
Intense and complete 72 3.8
Unknown 73 3.9
ER mean (SD)/median (IQR) 83 (17)/90 (80–95)
PgR mean(SD)/median (IQR) 51 (37)/60 (10–90)
Ki-67 mean(SD)/median (IQR) 15 (9)/14 (9–20)
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(HR, 9.55; 95% CI, 5.64–16.2; heterogeneity p value
0.002; Table 2).
Analysis exploring the association between clinico-
pathological variables and DFS in the first 5 years
after surgery and beyond the first 5 years of FUP
showed similar results (Additional file 1: Table S2).
We further focused our analyses on prognostic factors
associated with risk of late recurrence in ILCs, as no
data are available in literature on this topic.
Among all patients, 1426 women had at least 5 years
of FUP and remained disease-free in the first 5 years
after surgery.
In multivariable analysis, factors retaining significant
and independent prognostic value for risk of late DM
were nodal status, T stage, and Ki-67 LI (Table 2).
A sensitivity analysis was conducted excluding 45
HER2-positive tumors and 63 HER2 unknown tumors
obtaining similar results (data not shown).
Similar results were obtained also in multivariable ana-
lyses for DFS (Additional file 1: Table S2).
Figure 1a shows the relationship between Ki-67 LI (log
transformed) and risk of DM between years 5 and 10,
together with a representation of the frequency distribu-
tion of Ki-67 LI in the group of ILCs analyzed.
It is evident that there is a steady rising of the risk of
DM with increasing values of Ki-67 LI.
Ki-67 LI, categorized as below or equal and above
20%, stratified ILC patients in two groups with signifi-
cantly different risk of late distant recurrence (Gray test
p value 0.008; HR, 1.81; 95% CI 1.19–2.75; Fig. 1b).
The absolute risk of DM in years 5 to 10 of FUP was
5.6% (95% CI, 4.1–7.5) in the Ki-67 < 20% group and
10.5% (95% CI, 7.1–14.6) in the Ki-67 ≥ 20% group
(Fig. 1b).
Ki-67 also stratified the prognosis of ILC patients sub-
grouped according to lymph node status (pN0 and pN1/
2/3; Fig. 1c).
In lymph node–negative ILCs, tumors with Ki-
67 ≥ 20% had a risk of late DM almost three times
higher than those with Ki-67 < 20% (HR, 2.88; 95% CI,
1.29–6.45; Table 3).
In lymph node–positive tumors, the risk of late DM
was 50% higher in tumors with Ki-67 ≥ 20% (HR, 1.52;
95% CI, 0.85–2.72; Table 3).
Table 2 Prognostic factors of early (≤ 5 years) and late (> 5 years) distant recurrences in ILCs, univariable and multivariable analysis
≤ 5 years > 5 years Heterogeneity
p value
(univariate
analyses)
Univariable analysis Univariable analysis Multivariable analysis
for late DM (> 5 years)
N Distant
events/PY
HR 95% CI p
value
N Distant
events/PY
HR 95% CI p
value
HR 95% CI p
value
Ki-67 (%)
< 20% 1375 70/6110 Ref. 1060 52/4046 Ref. Ref.
≥ 20% 497 46/2165 1.85 1.27–2.68 0.001 366 37/1562 1.81 1.19–2.75 0.005 1.90 1.17–3.07 0.009 0.93
HER2a
Not
expressed
1727 102/7629 Ref. 1318 77/5009 Ref. Ref.
Intense and
complete
72 10/300 2.38 1.26–4.52 0.008 45 3/159 1.13 0.35–3.62 0.84 1.18 0.34–4.06 0.79 0.43
pN
pN0 1103 16/5017 Ref. 901 29/3397 Ref. Ref.
pN1/2/3 769 100/3259 9.55 5.64–16.2 < 0.001 525 60/2212 3.21 2.06–5.01 < 0.001 2.70 1.68–4.34 < 0.001 0.002
Gradeb
G1/2 1511 64/6767 Ref. 1190 71/4649 Ref. Ref.
G3 209 27/871 3.24 2.07–5.07 < 0.001 135 8/568 0.89 0.44–1.83 0.76 0.55 0.26–1.16 0.12 0.003
pT
pT1/2 1672 85/7447 Ref. 1298 68/5140 Ref. Ref.
pT3/4 200 31/828 3.24 2.15–4.90 < 0.001 128 21/468 3.31 2.05–5.33 < 0.001 2.42 1.42–4.12 0.001 0.91
PgR
< 20% 555 57/2392 Ref. 402 26/1727 Ref. Ref.
≥ 20% 1317 59/5883 0.42 0.29–0.61 < 0.001 1024 63/3881 1.10 0.69–1.74 0.69 1.03 0.64–1.67 0.90 0.001
aFor patients with HER2, unknown 4 events occurred within the first 5 years of FUP and 9 beyond 5 years
bFor patients with grade, unknown 25 events occurred within the first 5 years of FUP and 10 beyond 5 years
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In the group of lymph node–negative tumors with Ki-
67 < 20% (701 of 1426 ILCs), there was a very low inci-
dence of late DM (absolute distant recurrence risk in
years 5 to 10, 2.5%; 95% CI, 1.3–4.3; Fig. 1c).
Lymph node–positive tumors with Ki-67 ≥ 20% dis-
played the highest incidence of late DM (absolute distant
recurrence risk in years 5 to 10, 15.5%; 95% CI, 9.8–22.5;
Fig. 1c).
Similarly, Ki-67 LI stratified DFS of ILC patients sub-
grouped by lymph node status (Additional file 1: Table S3).
These data show that in ILCs, KI-67 LI retained a sig-
nificant and unchanged prognostic value for risk of DM
in the late period of FUP as compared with the first 5
years after surgery, whereas positive nodal status had a
significantly reduced prognostic value in late follow-up.
Finally, we performed a sensitivity analysis in which
we analyzed separately patients that received or not ad-
juvant chemotherapy and we confirmed similar results
in both groups (data not shown).
Features associated with late distant recurrence risk are
partially different in ILCs and IDCs
To confirm that these findings are specific for ILCs, we
analyzed a cohort of patients with IDCs, 1:1 matched to
patients in the ILC cohort according to patients’ age
group, nodal status, T stage, year of surgery, and tumor
subtype classification (luminal A-like and luminal B-like
according to St. Gallen 2013 classification).
The flowchart for the patient’s selection and baseline
characteristics of the matched cohorts of ductal and
lobular cancers are shown respectively in Additional file 1:
Figure S1 and Table S4.
We found that in IDCs, the strength of association
between nodal status and the risk of DM was not sig-
nificantly different in the first 5 years and in the sub-
sequent period of follow-up (HR in first 5 years, 5.80;
95% CI, 3.70–9.08; HR after 5 years, 7.13; 95% CI,
3.69–13.8; p heterogeneity 0.61; Additional file 1:
Table S5).
Fig. 1 Cumulative incidence of distant recurrences after the first 5 years from surgery in ILCs, according to Ki-67 Index as continuum after log-
transformation (a); according to Ki-67 index categorized as < 20% or ≥ 20% (b); and according to nodal status and Ki-67 index categorized as <
20% or ≥ 20% (c)
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Ki-67 LI was significantly associated with risk of DM
only in the first 5 years of follow-up (HR, 2.73; 95% CI,
1.89–3.94; Additional file 1: Table S5) and lost its prog-
nostic value in the subsequent period of FUP (HR, 1.57;
95% CI, 0.91–2.70; p heterogeneity 0.10; Additional file 1:
Table S5).
KI-67 LI provided significant independent prognostic
information when added to the CTS5 in ILCs
The Clinical Treatment Score post 5 years (CTS5) is
built on nodal status, tumor size, grade, and patient age,
and it has been demonstrated that it is significantly asso-
ciated with late DM risk in ER+BCs.
In populations affected in the vast majority of cases by
IDCs, CTS5 score was able to identify three groups of
patients with respectively low risk of late distant metas-
tases (i.e., late risk of DM < 5% if CTS5 was < 3.13),
intermediate (i.e., DM risk between 5 and 10% when
CTS5 ranged between 3.13 and 3.86), and high risk (DM
risk > 10% when CTS5 > 3.86) [24, 25].
We therefore investigated whether CTS5 was also as-
sociated with late DM risk of ILCs. For this analysis, we
excluded patients with missing data needed to calculate
CTS5, leading to a sample size of 1301 women.
Figure 2a shows the actual risk of late DM in patients
with ILCs categorized in the three groups of risk pre-
dicted using the CTS5 cut-offs identified and validated
in the original paper [24, 25].
Patients in both low and intermediate CTS5 groups
had an actual DM risk higher than predicted: the abso-
lute risk of DM in years 5 to 10 was respectively 5.7%
(95% CI 4.2–7.5%) in the low CTS5 group and 24.7%
(95% CI 13.4–37.8%) in the intermediate CTS5 group
(Fig. 2a).
Only 3 patients were classified in the CTS5 high-risk
group, but they did not have any recurrence.
We assessed whether other clinical and pathological
variables could improve the prognostic value of the
CTS5 score in ILCs.
The ER and PgR levels and HER2 status did not pro-
vide significant prognostic value for late DM when
added to CTS5 assessed as continuous variable (Add-
itional file 1: Table S6).
The only variable that provided significant independ-
ent prognostic information when added to the CTS5
was the Ki-67 LI after logarithmic transformation (p
value LRT 0.04; Additional file 1: Table S6).
Combining the CTS5 and ln(Ki-67) values, we ob-
tained a final combined score that we named KiCTS5
(i.e., Ki-67 index and Clinical Treatment Score post 5
years).
The relationship between KiCTS5 and risk of DM be-
tween years 5 and 10 is shown in Fig. 2c, together with a
representation of the frequency distribution of KiCTS5
values in the group of ILCs analyzed. It is evident that
there is a steady rising of the risk of distant recurrence
with increasing values of KiCTS5.
Table 3 Prognostic factors of late (> 5 years) distant recurrences in ILCs by lymph node status
pN0 (N = 901) pN1/2/3 (N = 525) p value for
interaction
with pN
Multivariable analysis Multivariable analysis
N Events/PY HR 95% CI p value N Events/PY HR 95% CI p value
Ki-67 (%)
< 20% 701 15/2584 Ref. 359 37/1462 Ref.
≥ 20% 200 14/812 2.88 1.29–6.45 0.01 166 23/750 1.52 0.85–2.72 0.16 0.06
HER2a
Not expressed 846 24/3116 Ref. 472 53/1893 Ref.
Intense and complete 26 2/85 3.48 0.80–15.1 0.10 19 1/74 0.52 0.07–3.85 0.52 0.21
Gradeb
G1/2 791 23/2993 Ref. 399 48/1657 Ref.
G3 72 3/279 0.63 0.18–2.18 0.46 63 5/289 0.52 0.21–1.29 0.16 0.19
pT
pT1/2 864 24/3272 Ref. 434 44/1868 Ref.
pT3/4 37 5/125 3.26 1.24–8.57 0.02 91 16/344 2.04 1.15–3.64 0.02 0.09
PgR
< 20% 245 5/1005 Ref. 157 21/722 Ref.
≥ 20% 656 24/2391 1.81 0.69–4.77 0.23 368 39/1490 0.75 0.43–1.32 0.32 0.14
aTwenty-nine patients pN0 with missing information (3 events/195 PY), 34 patients pN1/2/3 with missing information (6 events/244 PY)
bThirty-eight patients pN0 with missing information (3 events/124 PY), 63 patients pN1/2/3 with missing information (7 events/266 PY)
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ILC patients categorized in three groups on the basis
of KiCTS5 tertiles—low, intermediate, and high
KiCTS5—had significantly different risk of late distant
recurrence (Gray test p value < 0.001; Fig. 2b).
The group of patients with low KiCTS5 had a 1.9%
(95% CI, 0.7–4.2) absolute risk of DM in years 5 to 10 of
follow-up (Fig. 2b). Patients with intermediate KiCTS5
had an absolute risk of DM of 4.8% (95% CI, 2.7–7.9)
while patients with high KiCTS5 had an absolute risk of
12.8% (95% CI, 9.3–16.8) (Fig. 2b).
Discussion
The risk of BC recurrence varies considerably over time,
being strongly influenced by clinical and pathological
variables. The main factor that influences the pattern of
BC recurrence over time is its hormone receptor status
[11, 32, 33].
Patients with ER-positive tumors continue to have a
higher risk of relapse, including distant metastases, dur-
ing years 5 to 25 [11, 33].
Studies performed to identify factors associated with
higher risk of recurrence after 5 years of endocrine
therapy included mainly IDCs, and uncertainty remains
on their validity for other rare BC subtypes [ 11–13, 24,
34–37].
Here we report for the first time an analysis of the as-
sociation between clinico-pathological factors and the
risk of late DM, performed specifically in ILCs. Similar
to previous studies, mainly conducted in IDCs, we found
that nodal status and T stage retained a significant prog-
nostic value beyond the first 5 years of follow-up.
A relevant difference, however, is that in ILCs, positive
nodal status had an impressively lower prognostic value
in late follow-up period as compared with the first 5
years after surgery.
On the contrary, the strength of association between Ki-
67 LI and risk of DM did not significantly change over
time and Ki-67 LI was able to stratify the prognosis of pa-
tients with both node-negative and node-positive disease.
Since our data show that in ILCs, nodal status alone is
not useful to accurately predict the risk of late recurrence,
we therefore combined several clinico-pathological factors
to obtain a score with stronger prognostic value for late
recurrence. Using a statistical parsimoniuous approach
Fig. 2 Cumulative incidence of distant recurrences after the first 5 years from surgery in ILCs, according to CTS5-predicted groups of risk—low
risk (CTS5 < 3.13 and predicted DM risk < 5%), intermediate (3.13 < CTS5 < 3.86 and predicted DM risk between 5 and 10%), and high risk (CTS5 >
3.86 and predicted DM risk > 10%)—(a); according to KiCTS5 tertiles (b); and according to KiCTS5 as continuum (c)
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that allows to avoid overfitting, we obtained a combined
score that integrates the previously validated CTS5 score
with Ki-67 LI [38]. This score was able to stratify the prog-
nosis of ILC patients in the late follow-up period and to
identify a large group of patients with ILC who have a very
low risk of late DM (650 of 1301 patients, with a cumula-
tive distant recurrence risk of 2.6% during years 5 to 10).
The reasons why tumors in more advanced stage and
with higher Ki-67 LI at diagnosis retain a higher risk of
relapse after 5 years of endocrine treatment are un-
known. A higher tumor burden at diagnosis could be as-
sociated with a higher amount of biological tumor
heterogeneity [39]. Higher tumor Ki-67 could reflect
deeper alterations of the mechanisms that regulate the
cell cycle [ 40, 41].
It could be speculated that both these conditions are
responsible for a lower degree of tumor endocrine re-
sponsiveness, leading to an incomplete eradication of
micrometastases that restart growth when treatments
are stopped. In this regard, it has been demonstrated
that alteration of the mechanisms that control cell cycle,
and in particular of the cyclin D/cyclin-dependent ki-
nases 4 and 6 (CDK4/6)/retinoblastoma (Rb) pathway, is
one of the most relevant mechanisms of endocrine re-
sistance in metastatic BCs, with some data obtained
from neoadjuvant treatments [42–44].
A strength of our study is that it has been performed
in a single institution. All included patients had patho-
logical evaluation carried out by the same team of pa-
thologists, ensuring consistent pathological reporting.
We had a very large cohort of ILCs with a considerable
number of late distant recurrences.
Yet our study has several limitations.
Similar to other studies of this kind so far published,
the recurrence rates reported here are in women who
were scheduled to receive at least 5 years of endocrine
therapy, not in those who actually completed treatment,
because detailed data on treatment adherence were not
available.
Furthermore, after 2005, data on the efficacy of ex-
tended adjuvant endocrine (EET) treatment in nodal
positive, ER+ BC have become available [29]. After
this period, some patients treated in our institute with
ER+ and node-positive tumors or tumors with node-
negative but worse prognostic features started to
receive extended endocrine treatment (tumors diag-
nosed and treated 5 years earlier). The percentage of
recurrences observed in our data are therefore derived
from a cohort of patients that includes also a sub-
group treated for more than 5 years. The number of
patients that received EET included in our analysis is
limited, but we are not able to precisely quantify it:
this represents a weakness shared by almost all stud-
ies to date performed in such field.
However, it seems unlikely that such weaknesses
would have a substantial effect on the generalizability of
our findings regarding the association between the vari-
ables analyzed and the risk of late recurrences in ILCs.
Obviously, further validation of the prognostic value of
KiCST5 score in an independent cohort of patients with
ILCs is needed, especially to evaluate whether and how
much the reported interlaboratory variability in the as-
sessment of Ki67-LI could limit the generalizability of
the prognostic value of the KiCST5.
Conclusion
The main finding of our analysis is that ILCs display
specific characteristics in terms of relationship between
clinical and pathological features and risk of late
recurrence.
Future research that focused on the evaluation of fac-
tors affecting BC late recurrence risk should take into
account BC histological subtypes as a relevant variable.
From a clinical point of view, given the significant loss
of prognostic value of nodal status for late recurrence
risk in ILCs, a broader assessment including other
clinico-pathological features, and in particular Ki-67
index, is probably needed to better estimate the late DM
risk of patients, that is of great importance for selecting
patients suitable or not for extended adjuvant endocrine
therapy (EET).
Indeed, data available from RCTs showed that EET
significantly reduced the risk of late DM in patients’
populations with endocrine responsive BCs, but the
absolute amount of such reduction is limited on aver-
age [5–10].
Since there are no definitive predictive biomarkers
useful to identify patients that derive benefit from EET,
the choice to administer or not EET relies on a cost-
benefit assessment done case by case and that largely de-
pends on the estimate of the patients’ residual risk of
DM after the first 5 years of endocrine treatment [45].
In particular, patients with low risk of late DM could
be those to whom properly propose to avoid EET [45].
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